Methods of using low molecular weight heparins for prevention or

Details Methods of using low molecular weight heparins for prevention or Methods of using low molecular weight heparins for prevention or

1997-11-07

1999-06-01

Fonda, Kathleen K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 54, 514825, 536 21, 536 54, 536 55, A61K 31725, C08B 3710

Patent

active

059088370

ABSTRACT:
The present invention relates to pharmaceutical compositions for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.

REFERENCES:
patent: 4281108 (1981-07-01), Fussi
patent: 4401662 (1983-08-01), Lormeau et al.
patent: 4788307 (1988-11-01), Lormeau et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4889808 (1989-12-01), Rappaport
patent: 4973580 (1990-11-01), Mascellani et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5039529 (1991-08-01), Bergendal et al.
patent: 5110918 (1992-05-01), Casu et al.
Bergquist et al; Thromb. Res. 1983, 32:381-391.
Berk, B.C. et al., J. Am. Coll. Cardiol. 1991, 17:111B-117B.
Beutler, B. and A. Cerami, Ann. Rev. Immunol. 1989, 7:625-655.
Boneu, B. et al., Thrombosis Research, 1987, 46:845.
Bratt, G. et al. Thrombosis and Haemostasis 1985, 53:208.
Castano, L. and Eisenbarth, G.S. Annu. Rev. Immunol. 1990, 8:647-679.
Cohen, L.R. et al. Arthritis and Rheumatism 1985, 28:841-845.
Colman, R. W. et al. American Journal of Pathology 1976, 82(1):25-42.
Dillman et al. Mol. Biother. 1992, 4:117-121.
Ekre, H.-P. et al. Advances in Experimental Medicine and Biology 1992, 313:329-340.
Elias, D. et al. Proc. Natl. Acad Sci., U.S.A. 1990, 87:1576-1580.
Fareed et al; Ann. N.Y. Acad. Sci. 1989, 556:333-353.
Gervasi, G.B. et al., Arzneim.-Forsch./Drug Res. 1991, 41:410-413.
Goldberg, I.D. et al. Ann. N.Y. Acad. Sci. 1986, 463:289-291.
Gospodarowicz, D. et al. J. Biol. Chem. 1978, 253:3736-3743.
Holoshitz, Y. et al. Science 1983, 219:56.
Horvath, J. E. et al. Aust. N.Z. J. Med. 1975, 5(6):537-539.
Kiricuta, I. et al. Physiology Chemistry and Physics 1978, 10:247-253.
Larsen et al; J. Pharm. Exp. Ther. 1984, 231(2):373-378.
Larsen et al; J. Biol. Chem. 1989, 264(3):1570-1577.
Lider, O. et al. Eur. J. Immunol. 1990, 20:493-499.
Lider, O. et al. J. Clin. Invest. 1989 83:752-756.
Linhardt, R.J. et al, J. Biol. Chem. 1982, 257(13):7310-7313.
Linhardt, R. J. et al. J. Biol. Chem. 1988, 263(26):13090-13096.
Mattsson et al; Ann. N.Y. Acad. Sci. 1989, 556:323-332.
Matsuyama, T. et al., J. Virol. 1989, 63(6):2504-2509.
Michihiko, S. et al. Lancet 1989, 1(8648):1206-1207.
Naparstek, Y. et al. Nature 1984, 310:241-243.
Okamoto, T. et al. AIDS Res. Hum. Retroviruses 1989, 5(2):131-138.
Ono, K. and Lindsey, E.S. J. Thorac. Cardiovasc. Surg. 1969 45:225-229.
Pearson, C.M. Arthritis and Rheumatism 1964, 7:80.
Pearson, C.M., Proc. Soc. Exp. Biol. Med. 1956, 91:95.
Redini et al; Biochem. Pharmacol. 1988, 37(22):4257-4261.
Sy, M. S. et al. Cellular Immunology, 1983, 82:23-32.
Toivonen, M. L. et al., Meth. and Find. Exp. Clin. Pharmacol. 1982, 4(6):359-363.
Wallach, D. J. Immunology 1984, 132:2464-2469.
Westwick, J. et al. Thrombosis Research 1986, 42:435-447.
Wright, T.C., Jr. et al; J. Biol. Chem. 1989, 264(3):1534-1542.

Affiliated with

Also associated with

Rating

Methods of using low molecular weight heparins for prevention or does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using low molecular weight heparins for prevention or, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using low molecular weight heparins for prevention or will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-955033